ATE404201T1 - Glycinrezeptorantagonisten und ihre verwendung - Google Patents

Glycinrezeptorantagonisten und ihre verwendung

Info

Publication number: ATE404201T1
Authority: AT; Austria
Prior art keywords: treating; disclosed; dihydroquinoxaline; diones; animal
Prior art date: 1992-06-22

Application number

AT93916620T

Other languages

English (en)

Inventor

Eckard Weber

John F W Keana

Original Assignee

Univ California

State Of Oregon Through Oregon

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-06-22

Filing date

1993-06-17

Publication date

2008-08-15

1993-06-17 Application filed by Univ California, State Of Oregon Through Oregon filed Critical Univ California

2008-08-15 Application granted granted Critical

2008-08-15 Publication of ATE404201T1 publication Critical patent/ATE404201T1/de

Links

229940122165 Glycine receptor antagonist Drugs 0.000 title 1
239000002430 glycine receptor antagonist Substances 0.000 title 1
ABJFBJGGLJVMAQ-UHFFFAOYSA-N 1,4-dihydroquinoxaline-2,3-dione Chemical class C1=CC=C2NC(=O)C(=O)NC2=C1 ABJFBJGGLJVMAQ-UHFFFAOYSA-N 0.000 abstract 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
230000004770 neurodegeneration Effects 0.000 abstract 2
208000024827 Alzheimer disease Diseases 0.000 abstract 1
206010002091 Anaesthesia Diseases 0.000 abstract 1
208000019901 Anxiety disease Diseases 0.000 abstract 1
208000000094 Chronic Pain Diseases 0.000 abstract 1
206010010904 Convulsion Diseases 0.000 abstract 1
201000010374 Down Syndrome Diseases 0.000 abstract 1
239000004471 Glycine Substances 0.000 abstract 1
208000023105 Huntington disease Diseases 0.000 abstract 1
208000013016 Hypoglycemia Diseases 0.000 abstract 1
208000002193 Pain Diseases 0.000 abstract 1
208000028017 Psychotic disease Diseases 0.000 abstract 1
206010044688 Trisomy 21 Diseases 0.000 abstract 1
230000002411 adverse Effects 0.000 abstract 1
150000003863 ammonium salts Chemical class 0.000 abstract 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
230000037005 anaesthesia Effects 0.000 abstract 1
230000036506 anxiety Effects 0.000 abstract 1
230000008499 blood brain barrier function Effects 0.000 abstract 1
210000001218 blood-brain barrier Anatomy 0.000 abstract 1
210000003169 central nervous system Anatomy 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000036461 convulsion Effects 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
239000003257 excitatory amino acid Substances 0.000 abstract 1
230000002461 excitatory amino acid Effects 0.000 abstract 1
208000013403 hyperactivity Diseases 0.000 abstract 1
230000002218 hypoglycaemic effect Effects 0.000 abstract 1
230000001939 inductive effect Effects 0.000 abstract 1
208000014674 injury Diseases 0.000 abstract 1
208000028867 ischemia Diseases 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
208000015122 neurodegenerative disease Diseases 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
238000001356 surgical procedure Methods 0.000 abstract 1
230000008733 trauma Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
- C07D241/52—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
- C07D241/54—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Physics & Mathematics (AREA)
Cardiology (AREA)
Optics & Photonics (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

AT93916620T 1992-06-22 1993-06-17 Glycinrezeptorantagonisten und ihre verwendung ATE404201T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US90308092A	1992-06-22	1992-06-22
US99516792A	1992-12-22	1992-12-22
US6927493A	1993-05-28	1993-05-28

Publications (1)

Publication Number	Publication Date
ATE404201T1 true ATE404201T1 (de)	2008-08-15

Family

ID=27371510

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT93916620T ATE404201T1 (de)	1992-06-22	1993-06-17	Glycinrezeptorantagonisten und ihre verwendung

Country Status (15)

Country	Link
US (3)	US5514680A (de)
EP (1)	EP0647137B1 (de)
JP (1)	JP3301024B2 (de)
KR (1)	KR100304017B1 (de)
AT (1)	ATE404201T1 (de)
AU (1)	AU672617B2 (de)
CA (1)	CA2138026C (de)
DE (1)	DE69334237D1 (de)
DK (1)	DK0647137T3 (de)
ES (1)	ES2313714T3 (de)
FI (1)	FI120094B (de)
NO (1)	NO310022B1 (de)
NZ (1)	NZ254404A (de)
PT (1)	PT647137E (de)
WO (1)	WO1994000124A1 (de)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9100028D0 (en) *	1991-01-02	1991-02-20	Ici Plc	Compounds
GB9212308D0 (en) *	1992-06-10	1992-07-22	Ici Plc	Therapeutic compositions
US5834479A (en) *	1993-03-05	1998-11-10	Mayer; David J.	Method and composition for alleviating pain
CA2115792C (en)	1993-03-05	2005-11-01	David J. Mayer	Method for the treatment of pain
IL109397A0 (en) *	1993-04-28	1994-07-31	Schering Ag	Quinoxalinedione derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
GB9311948D0 (en) *	1993-06-10	1993-07-28	Zeneca Ltd	Substituted nitrogen heterocycles
US5631373A (en) *	1993-11-05	1997-05-20	State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon	Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones
EP0743855A1 (de) *	1994-01-03	1996-11-27	Acea Pharmaceuticals, Inc.	8-Aza,6-Aza und 6,8-Diaza - 1,4 dihydrochinoxalin -2,3-dione und deren Verwendung als Glycin/NMDARezeptor Antagonisten
FR2717805B1 (fr) *	1994-03-28	1996-05-10	Rhone Poulenc Rorer Sa	Dérivés de 5H-indeno[1,2-b]pyrazine-2,3-dione, leur préparation et les médicaments les contenant .
FR2717813B1 (fr) *	1994-03-28	1996-05-10	Rhone Poulenc Rorer Sa	Dérivés d'imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one, leur préparation et les médicaments les contenant .
FR2717811B1 (fr) *	1994-03-28	1996-04-26	Rhone Poulenc Rorer Sa	Dérivés d'imidazo[1,2-a]pyrazine-4-one, leur préparation et les médicaments les contenant.
FR2717812B1 (fr) *	1994-03-28	1996-05-10	Rhone Poulenc Rorer Sa	Indeno[1,2-e]pyrazine-4-ones, leur préparation et les médicaments les contenant.
HU217837B (hu) *	1994-05-18	2000-04-28	EGIS Gyógyszergyár Rt.	Savamidok, ezeket tartalmazó gyógyászati készítmények és eljárás a hatóanyagok előállítására
US5801168A (en) *	1994-06-09	1998-09-01	Zeneca Limited	Substituted nitrogen heterocycles
DE4428152A1 (de) *	1994-06-22	1996-01-04	Basf Ag	Neue Amido-chinoxalindione, ihrer Herstellung und Verwendung
EP0705834A1 (de) *	1994-07-27	1996-04-10	Ciba-Geigy Ag	Azaaliphatisch Überbrückte Chinoxalin-2,3-dione
US5597922A (en) *	1994-07-29	1997-01-28	State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon	Glycine receptor antagonist pharmacophore
EP0705835A1 (de) *	1994-09-01	1996-04-10	Ciba-Geigy Ag	Oxa- oder thiaaliphatisch überbrückte Chinoxalin-2,3-dione
GB9418443D0 (en) *	1994-09-13	1994-11-02	Pfizer Ltd	Therapeutic agents
GB9419318D0 (en) *	1994-09-24	1994-11-09	Pfizer Ltd	Therapeutic agents
US5801183A (en) *	1995-01-27	1998-09-01	State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon	Aza and aza (N-oxy) analogs of glycine/NMDA receptor antagonists
GB9604400D0 (en)	1996-03-01	1996-05-01	Pfizer Ltd	Compounds useful in therapy
US6191134B1 (en)	1996-06-05	2001-02-20	Warner-Lambert Company	Amide derivatives of substituted quinoxaline 2, 3-diones as glutamate receptor antagonists
WO1997049684A1 (en) *	1996-06-24	1997-12-31	Novo Nordisk A/S	Factor vii-binding reagent
CA2269807C (en) *	1996-10-24	2007-04-10	Novartis Ag	Substituted aminoalkanephosphonic acids
HUP0001311A3 (en) *	1997-02-18	2001-07-30	American Home Products Corp Ma	5-aminoalkoxy-1,4-dihydroquinoxaline-2,3-diones being dopamine agonists and pharmaceutical compositions containing them
US5922715A (en) *	1997-02-18	1999-07-13	American Home Products Corporation	5-aminoalkoxy-1, 4-dihydroquinoxaline-2, 3-diones
CA2286797C (en) *	1997-04-18	2008-07-15	Abbott Laboratories	A process for the preparation of highly pure 6,7-dichloro-5-nitro-2,3-dihydroquinoxaline-2,3-dione
IL125950A0 (en) *	1997-09-05	1999-04-11	Pfizer Prod Inc	Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
CA2314896C (en)	1997-12-22	2005-09-13	Euro-Celtique, S.A.	A method of preventing abuse of opioid dosage forms
US6375957B1 (en)	1997-12-22	2002-04-23	Euro-Celtique, S.A.	Opioid agonist/opioid antagonist/acetaminophen combinations
JP2001526228A (ja)	1997-12-22	2001-12-18	ユーロ−セルティーク，エス．エイ．	オピオイド作動薬／拮抗薬の併用
JP2002505288A (ja)	1998-03-02	2002-02-19	コセンシス，インコーポレイテッド	置換キナゾリンおよびアナログならびにそれらの使用
DE19814257A1 (de) *	1998-03-31	1999-10-07	Asta Medica Ag	Brauseformulierungen
WO2001041782A2 (en) *	1999-12-09	2001-06-14	Chiron Corporation	Method for administering a cytokine to the central nervous system and the lymphatic system
US6716449B2 (en)	2000-02-08	2004-04-06	Euro-Celtique S.A.	Controlled-release compositions containing opioid agonist and antagonist
HU229705B1 (en)	2000-02-08	2014-05-28	Euro Celtique Sa	Tamper-resistant oral opioid agonist formulations
EP1935421A1 (de)	2000-02-08	2008-06-25	Euro-Celtique S.A.	Kontrolliert freigesetzte Zusammensetzungen mit einem Opioid-Agonisten und einem Opioid-Antagonisten
US20050002986A1 (en) *	2000-05-12	2005-01-06	Robert Falotico	Drug/drug delivery systems for the prevention and treatment of vascular disease
US8236048B2 (en)	2000-05-12	2012-08-07	Cordis Corporation	Drug/drug delivery systems for the prevention and treatment of vascular disease
WO2002009736A1 (en) *	2000-07-27	2002-02-07	Washington University	Methods and agents for treating persistent pain
CA2424029C (en)	2000-09-29	2008-01-29	Cordis Corporation	Coated medical devices
UA81224C2 (uk)	2001-05-02	2007-12-25	Euro Celtic S A	Дозована форма оксикодону та її застосування
CN1525851A (zh)	2001-05-11	2004-09-01	��ҩ��޹�˾	抗滥用阿片样物质控释剂型
SI1416842T1 (sl) *	2001-07-18	2009-06-30	Euro Celtique Sa	Farmacevtske kombinacije oksikodona in naloksona
US20030044458A1 (en) *	2001-08-06	2003-03-06	Curtis Wright	Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030068375A1 (en)	2001-08-06	2003-04-10	Curtis Wright	Pharmaceutical formulation containing gelling agent
AU2002324624A1 (en)	2001-08-06	2003-02-24	Euro-Celtique S.A.	Sequestered antagonist formulations
ATE431738T1 (de)	2001-08-06	2009-06-15	Euro Celtique Sa	Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
WO2003015713A2 (en) *	2001-08-20	2003-02-27	Maiken Nedergaard	Treatment of glial tumors with glutamate antagonists
EP1298581A1 (de) *	2001-09-27	2003-04-02	C.S.E.M. Centre Suisse D'electronique Et De Microtechnique Sa	Verfahren und Anlage zum Berechnen von Neuronenwerten in einem neuronalen Netzwerk
EP1492505B1 (de)	2002-04-05	2015-06-03	Euro-Celtique S.A.	Pharmazeutische zubereitung enthaltend oxycodon und naloxon
US7815934B2 (en)	2002-09-20	2010-10-19	Alpharma Pharmaceuticals, Llc	Sequestering subunit and related compositions and methods
US20040082543A1 (en) *	2002-10-29	2004-04-29	Pharmacia Corporation	Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
US20040152694A1 (en) *	2003-02-04	2004-08-05	Istvan Kurucz	Methods and compositions for treating inflammatory disorders of the airways
US20040202717A1 (en)	2003-04-08	2004-10-14	Mehta Atul M.	Abuse-resistant oral dosage forms and method of use thereof
MY135852A (en)	2003-04-21	2008-07-31	Euro Celtique Sa	Pharmaceutical products
EP1663229B1 (de)	2003-09-25	2010-04-14	Euro-Celtique S.A.	Pharmazeutische kombinationen von hydrocodon und naltrexon
EP1604666A1 (de) *	2004-06-08	2005-12-14	Euro-Celtique S.A.	Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
CA2916869A1 (en)	2004-06-12	2005-12-29	Jane C. Hirsh	Abuse-deterrent drug formulations
EP1702558A1 (de) *	2005-02-28	2006-09-20	Euro-Celtique S.A.	Verfahren und Vorrichtung zur Darmtätigkeitserfassung
SI2719378T1 (sl)	2006-06-19	2016-11-30	Alpharma Pharmaceuticals Llc	Farmacevtski sestavki
US20100151014A1 (en) *	2008-12-16	2010-06-17	Alpharma Pharmaceuticals, Llc	Pharmaceutical composition
US8623418B2 (en)	2007-12-17	2014-01-07	Alpharma Pharmaceuticals Llc	Pharmaceutical composition
RU2478388C2 (ru) *	2008-07-07	2013-04-10	Еуро-Селтик С.А.	Фармацевтическая композиция, содержащая опиоидный антагонист, для лечения задержки мочи
MY152279A (en)	2009-03-10	2014-09-15	Euro Celtique Sa	Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US10668060B2 (en)	2009-12-10	2020-06-02	Collegium Pharmaceutical, Inc.	Tamper-resistant pharmaceutical compositions of opioids and other drugs
EP2338492A1 (de)	2009-12-24	2011-06-29	Universidad del Pais Vasco	Verfahren und Zusammensetzung zur Behandlung von Alzheimer
ME02874B (de)	2010-12-22	2018-04-20	Purdue Pharma Lp	Gekapselte manipulationssichere Darreichungsformen mit gesteuerter Freisetzung
PH12013501345A1 (en)	2010-12-23	2022-10-24	Purdue Pharma Lp	Tamper resistant solid oral dosage forms
US9737531B2 (en)	2012-07-12	2017-08-22	Glytech, Llc	Composition and method for treatment of depression and psychosis in humans
CN102936223A (zh) *	2012-11-02	2013-02-20	江苏中丹药物研究有限公司	5-碘-2-甲基苯并咪唑的合成方法及纯化方法
CN105164107B (zh) *	2012-12-20	2017-12-05	卢庆彬	用于与放射结合使用的放射增敏剂化合物
MX2015010041A (es)	2013-02-05	2015-10-30	Purdue Pharma Lp	Formulacion farmaceuticas resistentes a la alteracion.
US10751287B2 (en)	2013-03-15	2020-08-25	Purdue Pharma L.P.	Tamper resistant pharmaceutical formulations
CN103275021B (zh) *	2013-05-24	2015-05-20	东北农业大学	N-二氯乙酰基-6,7-二氯-1,2,3,4-四氢喹喔啉及其制备方法
US10071089B2 (en)	2013-07-23	2018-09-11	Euro-Celtique S.A.	Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
EP3060557A1 (de)	2013-10-23	2016-08-31	Bayer CropScience Aktiengesellschaft	Substituierte chinoxalin-derivate als schädlingsbekämpfungsmittel
US9737530B1 (en)	2016-06-23	2017-08-22	Collegium Pharmaceutical, Inc.	Process of making stable abuse-deterrent oral formulations
MX393950B (es)	2017-06-12	2025-03-24	Glytech Llc	Composicion y metodo para el tratamiento de la depresion y psicosis en humanos
WO2019018241A1 (en) *	2017-07-18	2019-01-24	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	RECEPTOR MODULATORS AND METHODS OF USE THEREOF
CN109678727A (zh) *	2018-12-26	2019-04-26	深圳市华先医药科技有限公司	一种微通道硝化反应合成2-乙基-5-硝基苯胺的方法
US11939302B2 (en) *	2020-10-21	2024-03-26	The Governors Of The University Of Alberta	Compounds for the treatment of Alzheimer's disease

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3992378A (en) *	1973-12-26	1976-11-16	Eli Lilly And Company	Fluoralkyl quinoxadinediones
US3962440A (en) *	1973-12-26	1976-06-08	Eli Lilly And Company	Quinoxaline compounds as hypnotic agents
DE2446543A1 (de) *	1974-09-28	1976-04-15	Hoechst Ag	Wasserunloesliche monoazomethinfarbstoffe, verfahren zu ihrer herstellung und ihre verwendung
DE2451049A1 (de) *	1974-10-26	1976-04-29	Hoechst Ag	Perinon-verbindungen, verfahren zu ihrer herstellung und ihre verwendung als farbmittel
DE2847285A1 (de) *	1978-10-31	1980-05-14	Hoechst Ag	Monoazoverbindungen, verfahren zu ihrer herstellung und ihre verwendung
US4659713A (en) *	1984-10-01	1987-04-21	International Minerals & Chemical Corp.	Quinoxalinedione compounds useful for controlling coccidiosis
US4803270A (en) *	1986-03-10	1989-02-07	Sumitomo Chemical Company, Limited	Process of producing fluoroaniline derivatives
US4812458A (en) *	1986-09-16	1989-03-14	A/S Ferrosan	6,7-disubstituted-2,3-dihydroxyquinoxaline compounds, pharmaceutical compositions thereof, and their use as neuroleptics
IE66149B1 (en) *	1986-09-16	1995-12-13	Novo Nordisk As	Quinoxaline compounds and their preparation and use
DK146787A (da) *	1987-03-23	1988-09-24	Ferrosan	Heterocykliske forbindelser, deres fremstilling og anvendelse
NO179551C (no) *	1987-11-10	1996-10-30	Novo Nordisk As	Analogifremgangsmåte for fremstilling av terapeutisk virksomme kinoxalinforbindelser
DK160941C (da) *	1988-06-28	1991-10-21	Novo Nordisk As	Kondenserede 2,3-dihydroxypyraziner, fremgangsmaade til deres fremstilling og farmaceutiske praeparater, hvori forbindelserne indgaar
DK716188D0 (da) *	1988-12-22	1988-12-22	Ferrosan As	Quinoxalinforbindelser, deres fremstilling og anvendelse
DK715888D0 (da) *	1988-12-22	1988-12-22	Ferrosan As	Quinoxalinforbindelser, deres fremstilling og anvendelse
US5308845A (en) *	1988-12-22	1994-05-03	Novo Nordisk A/S	Quinoxaline compounds and their preparation and use
US5187171A (en) *	1989-01-09	1993-02-16	G. D. Searle & Co.	Use of a glycine b partial agonist as an antipsychotic
JP2722250B2 (ja) *	1989-05-30	1998-03-04	興和株式会社	新規なジアミン化合物及びこれを含有する脳機能障害改善剤
US5055465A (en) *	1989-05-31	1991-10-08	Berlex Laboratories, Inc.	Imidazoquinoxalinones, their aza analogs and process for their preparation
US4994460A (en) *	1989-06-01	1991-02-19	Bristol-Myers Squibb Co.	Agents for treatment of brain ischemia
US5055470A (en) *	1989-06-01	1991-10-08	Bristol-Myers Squibb Co.	Method of treatment of ischemia in brain
US4975430A (en) *	1989-06-16	1990-12-04	The State Of Oregon Acting By And Through The State Board Of Education On Behalf Of The Oregon Health Sciences University	CNQX and its analogs as therapeutics for degenerative neural diseases
US5198461A (en) *	1989-12-11	1993-03-30	Neurosearch A/S	Isatine derivatives, their preparation and use
HU214591B (hu) *	1989-12-14	1998-04-28	Novartis Ag.	Eljárás egy naftoxazinszármazék malonátsójának és az ilyen hatóanyagot tartalmazó gyógyszerkészítmények előállítására
DK69790D0 (da) *	1990-03-16	1990-03-16	Novo Nordisk As	Heterocykliske forbindelser, deres fremstilling af anvendelse
US5268378A (en) *	1990-05-31	1993-12-07	Merck Sharp & Dohme, Limited	Dioxo-tetrahydroquinoline derivatives
GB9022785D0 (en) *	1990-10-19	1990-12-05	Merck Sharp & Dohme	Therapeutic agents
HU221425B (en) *	1990-11-06	2002-10-28	Yamanouchi Pharma Co Ltd	Condensed pyrazine derivatives, process for their production and pharmaceutical preparations containing these compounds
AU9049391A (en) *	1990-12-20	1992-07-22	Warner-Lambert Company	2-acylamido derivatives of 3,4-dihydro-3-oxo-quinoxaline having pharmaceutical activity
PT99864B (pt) *	1990-12-21	1999-06-30	Schering Ag	Processo para a preparacao de novas composicoes farmaceuticas contendo antagonistas de receptor de quisqualato
GB9100028D0 (en) *	1991-01-02	1991-02-20	Ici Plc	Compounds
US5118675A (en) *	1991-02-15	1992-06-02	American Home Products Corporation	Quinoxaline phosphono-amino acids
JP3465794B2 (ja) *	1991-02-27	2003-11-10	メレルファーマスーティカルズインコーポレイテッド	Ｎｍｄａ拮抗剤
DK73091D0 (da) *	1991-04-22	1991-04-22	Novo Nordisk As	Quinoxalinforbindelser, deres fremstilling og anvendelse
US5196421A (en) *	1991-06-05	1993-03-23	Eli Lilly And Company	Excitatory amino acid receptor antagonists in methods for the use thereof
PT101004B (pt) *	1991-10-26	1999-10-29	Schering Ag	Derivados da quinoxalina, processo para a sua preparacao e composicoes farmaceuticas que os contem
DE4217952A1 (de) *	1992-05-30	1993-12-02	Basf Ag	Chinoxalin-2,3(1H,4H)-dione
CA2098446A1 (en) *	1992-09-30	1994-03-31	Eckard Weber	2,5-dihydro-2,5-dioxo-1h-azepines and 2,5-dihydro-2-oxo-1h-azepines and the use thereof as excitatory amino acid and glycine receptor antagonists
US5352683A (en) *	1993-03-05	1994-10-04	Virginia Commonwealth University Medical College Of Virginia	Method for the treatment of chronic pain
IL109397A0 (en) *	1993-04-28	1994-07-31	Schering Ag	Quinoxalinedione derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same

1993
- 1993-06-17 EP EP93916620A patent/EP0647137B1/de not_active Expired - Lifetime
- 1993-06-17 DK DK93916620T patent/DK0647137T3/da active
- 1993-06-17 ES ES93916620T patent/ES2313714T3/es not_active Expired - Lifetime
- 1993-06-17 AT AT93916620T patent/ATE404201T1/de active
- 1993-06-17 KR KR1019940704688A patent/KR100304017B1/ko not_active Expired - Fee Related
- 1993-06-17 DE DE69334237T patent/DE69334237D1/de not_active Expired - Lifetime
- 1993-06-17 NZ NZ254404A patent/NZ254404A/xx not_active IP Right Cessation
- 1993-06-17 AU AU46412/93A patent/AU672617B2/en not_active Ceased
- 1993-06-17 WO PCT/US1993/005859 patent/WO1994000124A1/en not_active Ceased
- 1993-06-17 JP JP50247594A patent/JP3301024B2/ja not_active Expired - Fee Related
- 1993-06-17 PT PT93916620T patent/PT647137E/pt unknown
- 1993-06-17 CA CA002138026A patent/CA2138026C/en not_active Expired - Lifetime
- 1993-11-05 US US08/148,259 patent/US5514680A/en not_active Expired - Lifetime
1994
- 1994-12-20 NO NO944942A patent/NO310022B1/no not_active IP Right Cessation
- 1994-12-21 FI FI946005A patent/FI120094B/fi not_active IP Right Cessation
1995
- 1995-03-17 US US08/405,708 patent/US5620979A/en not_active Expired - Lifetime
- 1995-03-17 US US08/405,713 patent/US5622952A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
AU672617B2 (en)	1996-10-10
CA2138026C (en)	2003-09-09
FI120094B (fi)	2009-06-30
NO944942L (no)	1995-02-22
WO1994000124A1 (en)	1994-01-06
EP0647137B1 (de)	2008-08-13
JP3301024B2 (ja)	2002-07-15
NO310022B1 (no)	2001-05-07
DE69334237D1 (de)	2008-09-25
CA2138026A1 (en)	1994-01-06
US5514680A (en)	1996-05-07
PT647137E (pt)	2008-11-24
ES2313714T3 (es)	2009-03-01
JPH08501283A (ja)	1996-02-13
NZ254404A (en)	1997-08-22
AU4641293A (en)	1994-01-24
EP0647137A1 (de)	1995-04-12
NO944942D0 (no)	1994-12-20
US5622952A (en)	1997-04-22
US5620979A (en)	1997-04-15
FI946005L (fi)	1995-02-21
FI946005A0 (fi)	1994-12-21
EP0647137A4 (de)	1998-09-16
DK0647137T3 (da)	2008-12-08
KR100304017B1 (ko)	2001-11-22

Legal Events

Date

Code

Title

Description

2009-06-15

UEP

Publication of translation of european patent specification

Ref document number: 0647137

Country of ref document: EP

Publication	Publication Date	Title
ATE404201T1 (de)	2008-08-15	Glycinrezeptorantagonisten und ihre verwendung
NZ276892A (en)	2000-01-28	Quinoxalinedione derivatives, preparation and use in pharmaceutical compositions thereof
WO1995018616A3 (en)	1995-12-21	8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/nmda receptor
WO1996022990A3 (en)	1996-10-10	Aza and aza (n-oxy) analogs of glycine/nmda receptor antagonists
EP0662827A4 (de)	1997-12-03	Therapeutische und diagnostische verfahren und zusammensetzungen auf der basis von notch-proteinen und nukleinsäuren.
ATE355374T1 (de)	2006-03-15	Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ATE185268T1 (de)	1999-10-15	Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
DE06075479T1 (de)	2006-11-16	Vorbeugung und Behandlung von amyloidogener Krankheit
ATE219363T1 (de)	2002-07-15	Lösliche prodrugs von paclitaxel
ATE401395T1 (de)	2008-08-15	Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren
IL208184A0 (en)	2010-12-30	Glp-1, and methods for treating diabetes
ES2162615T3 (es)	2002-01-01	Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
BR0311558A (pt)	2007-04-27	composto ou sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, métodos para afetar os receptores de glutamato metabotrópicos ligados a camp, para administrar uma quantidade eficaz de um composto e para tratar um distúrbio neurológico e psiquiátrico em um paciente, e, formulação farmacêutica
BR0210122A (pt)	2004-06-15	Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
BRPI0406883A (pt)	2006-01-03	Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
TR200002570T2 (tr)	2000-12-21	Glisin naklini önleyiciler
DK1151009T3 (da)	2008-01-28	Antimikrobielt/endotoksin-neutraliserende polypeptid
BRPI0416882A (pt)	2007-02-27	composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
KR950032171A (ko)	1995-12-20	옥소피리디닐퀴녹살린 유도체
ATE285773T1 (de)	2005-01-15	Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten
WO2025080877A3 (en)	2025-06-05	Therapeutic peptides
ATE147978T1 (de)	1997-02-15	Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
BR0213633A (pt)	2004-08-24	Método e composto para tratar de uma doença associada com recrutamento e/ou ativação aberrante de leucócitos
DE102018110543A1 (de)	2019-11-07	D-enantiomere Peptide zur anti-inflammatorischen Behandlung der Amyotrophen Lateralsklerose (ALS) und anderer von neuro-inflammation getriebener Erkrankungen
ATE201993T1 (de)	2001-06-15	Verwendung von olanzapine zur herstellung eines arzneimittels zur behandlung der zerebralen fokalen ischämie